Last reviewed · How we verify
Human Umbilical Mesenchymal Stem Cells
At a glance
| Generic name | Human Umbilical Mesenchymal Stem Cells |
|---|---|
| Sponsor | First Affiliated Hospital of Wannan Medical College |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Procedural pain
- Arthralgia
- fever
- Joint swelling
- headache
- Joint stiffness
- Post procedural contusion
- Post procedural haematoma
- dizziness
- transient increase of muscle tension
- Pyrexia
- Otitis media
Key clinical trials
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease (PHASE1, PHASE2)
- Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient (NA)
- Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis (PHASE1, PHASE2)
- A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome (PHASE1, PHASE2)
- Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke (PHASE1)
- Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture (PHASE1)
- Extracellular Vesicles for the Treatment of Syringomyelia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: